Incyte (INCY) Asset Writedowns and Impairment (2017)
Incyte's (INCY) quarterly Asset Writedowns and Impairment came in at $12.0 million in Q3 2017.
Powered by 
Analysis
Incyte (INCY) Asset Writedowns and Impairment (2017) Analysis & Trends
Incyte (INCY) has 1 years of Asset Writedowns and Impairment data on file, last reported at $12.0 million in Q3 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.31 Bn | 130.45 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.17 Bn | 77.17 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.25 Bn | 58.07 Bn | 1.37 Bn |
| 4 | Moderna | 58.27 Bn | 53.13 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - |
| 6 | BeOne Medicines | 40.01 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.26 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.37 Bn | 26.21 Bn | 358.27 Mn |
| 10 | Incyte | 25.53 Bn | 21.00 Bn | 1.57 Bn |